Reportlinker Adds Generic and Biogeneric Drugs for 15 Major Therapeutic Categories
NEW YORK, Jan. 12 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Generic and Biogeneric Drugs for 15 Major Therapeutic Categories
http://www.reportlinker.com/p0170918/Generic-and-Biogeneric-Drugs-for-15-Major-Therapeutic-Categories .html
This report reviews, analyzes and sizes the generic and biogeneric drug markets, particularly focusing on new biogeneric medicines.
This report assesses the generic prescription market and maps the competitive landscape. The market forecast section sizes the market and discusses the five-year revenue projection to 2013. The market is segmented by key therapeutic applications, into major world regions of U.S., EU, Japan and rest of world (ROW), with drugs identified by active ingredient and brand name (in parentheses). It covers the major therapeutic indications for generic medicines:
Allergy Drugs
CNS and Psychotherapeutic Drugs
Analgesics, NSAIDs and Antirheumatic Drugs
Cholesterol Reducers
Anesthesia Drugs
Diabetes Drugs
Anti-Convulsants
Gastrointestinal Drugs
Anti-Infectives
Hormonal Drugs
Cancer Drugs
Osteoporosis Drugs
Cardiovascular Drugs
Sleeping Agents & Sedatives
Primary information for this report was gathered from numerous sources including in-person interviews and discussions, telephone interviews, and surveys, attendance at business presentations at healthcare technical and financial conferences as well as through secondary research.
This market research study is designed for people that include marketers, business development, top executives, investors, VCs, consultants, R&D managers, entrepreneurs and the like. More than 200 detailed tables and figures provide key data about items such as revenues and market size, market share, segments and the like. This report includes 37 company profiles that provide the reader a snapshot of the companies' focus or activities. Internet links help readers access companies' own web sites for further review.
Targeted Company:
Actavis Group, Analiza Inc., Apotex, Aurobindo Pharma, Bedford Laboratories, Biocon, BioGeneriX Ag, Biopartners GmbH, Cangene Corporation, Dr. Reddy's Laboratories, Dragon Pharmaceuticals Inc., Hospira, Inc., Lupin Pharmaceuticals, Microbix Biosystems, Momenta Pharmaceuticals, Mylan Inc., Nichi-Iko Pharmaceutical, Nipro Pharma Corp., Orchid Chemicals and Pharmaceuticals Ltd., Par Pharmaceuticals, Perrigo, Pfizer, Phage Biotechnology Corp., Ranbaxy Laboratories, Ratiopharm, Reliance GeneMedix plc, Roxane Laboratories, Sandoz, Sawai Pharmaceutical Co., Stada Arzneimittel Ag, Taisho Pharmaceutical Industries, Taro Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Towa Pharmaceutical, URL Pharma, Watson Pharmaceuticals, Inc., Zydus Pharmaceuticals, Inc.
Table of Contents
Executive Summary
1. Global Market: Generic and Biogeneric Drugs
1.1 The Global Generic and Biogeneric Drug Landscape
1.1.1 Global Healthcare Spending
1.1.2 Global Prescription Volume for Generic and Biogeneric Drugs
1.1.3 Global Sales of Generic and Biogeneric Drugs
1.1.3.1 Global Sales of Generic and Biogeneric Drugs by Company
Table 1.1: Sales by Company, 2008
Figure 1.1: Market Positions (Share) by Company, 2008
1.1.3.2 Global Sales of Generic and Biogeneric Drugs by Category
1.1.3.2.1 Allergy Drugs
Table 1.2: Sales by Indication/Drug Name 2008
Figure 1.2: Market Positions (Share) by Drug Name, 2008
Table 1.3: Sales by Brand in $MM, 2008 - 2013
Figure 1.3: Sales by Brand, 2008 – 2013
1.1.3.2.2 Analgesics, NSAIDs and Antirheumatic Drugs
Table 1.4: Sales by Indication/Drug Name, 2008
Figure 1.4: Market Positions (Share) by Drug Name, 2008
Table 1.5: Sales by Brand in $MM, 2008 - 2013
Figure 1.5: Sales Growth by Brand, 2008 - 2013
1.1.3.2.3 Anesthetics
Table 1.6: Sales by Indication/Drug Name, 2008
Figure 1.6: Market Positions (Share) by Drug Name, 2008
Table 1.7: Sales of by Brand in $MM, 2008 - 2013
Figure 1.7: Sales Growth by Brand, 2008 - 2013
1.1.3.2.4 Anti-Convulsants
Table 1.8: Sales by Indication/Drug Name, 2008
Figure 1.8: Market Positions (Share) by Drug Name, 2008
Table 1.9: Sales by Brand in $MM, 2008 - 2013
Figure 1.9: Sales Growth by Brand, 2008 - 2013
1.1.3.2.5 Anti-Infectives
Table 1.10: Sales by Indication/Drug Name, 2008
Figure 1.10: Market Positions (Share) by Drug Name, 2008
Table 1.11: Sales by Brand in $MM, 2008 - 2013
Figure 1.11: Sales Growth by Brand, 2008 - 2013
1.1.3.2.6 Cancer Drugs
Table 1.12: Sales by Indication/Drug Name, 2008
Figure 1.12: Market Positions (Share) by Drug Name, 2008
Table 1.13: Sales by Brand in $MM, 2008 – 2013
Figure 1.13: Sales Growth by Brand, 2008 – 2013
1.1.3.2.7 Cardiovascular Drugs
Table 1.14: Sales of by Type/Drug Name, 2008
Figure 1.14: Market Positions (Share) by Drug Name, 2008
Table 1.15: Sales by Brand in $MM, 2008 - 2013
Figure 1.15: Sales Growth by Brand, 2008 – 2013
1.1.3.2.8 CNS and Psychotherapeutic Drugs
Table 1.16: Sales by Type/Drug Name, 2008
Figure 1.16: Market Positions (Share) by Drug Name, 2008
Table 1.17: Sales by Brand in $MM, 2008 - 2013
Figure 1.17: Sales Growth by Brand, 2008 – 2013
1.1.3.2.9 Cholesterol Reducers/Statins
Table 1.18: Sales by Type/Drug Name, 2008
Figure 1.18: Market Positions (Share) by Drug Name, 2008
Table 1.19: Sales by Brand in $MM, 2008 - 2013
Figure 1.19: Sales Growth by Brand, 2008 – 2013
1.1.3.2.10 Diabetes Drugs
Table 1.20: Sales by Type/Drug Name, 2008
Figure 1.20: Market Positions (Share) by Drug Name, 2008
Table 1.21: Sales by Brand in $MM, 2008 - 2013
Figure 1.21: Sales Growth by Brand, 2008 – 2013
1.1.3.2.11 Gastrointestinal Drugs/Proton Pump Inhibitors
Table 1.22: Sales by type/Drug Name, 2008
Figure 1.22: Market Positions (Share) by Drug Name, 2008
Table 1.23: Sales by Brand in $MM, 2008 – 2013
Figure 1.23: Sales Growth by Brand, 2008 – 2013
1.1.3.2.12 Hormonal Drugs
Table 1.24: Sales by Type/Drug Name, 2008
Figure 1.24: Market Positions (Share) by Drug Name, 2008
Table 1.25: Sales by Brand in $MM, 2008 - 2013
Figure 1.25: Sales Growth by Brand, 2008 – 2013
1.1.3.2.13 Osteoporosis and Hypercalcemia Drugs
Table 1.26: Sales by Type/Drug Name, 2008
Figure 1.26: Market Positions (Share) by Drug Name, 2008
Table 1.27: Sales by Brand in $MM, 2008 - 2013
Figure 1.27: Sales Growth by Brand, 2008 – 2013
1.1.3.2.14 Sleeping Agents
Table 1.28: Sales by Type/Drug Name, 2008
Figure 1.28: Market Positions (Shape) by Drug Name, 2008
Table 1.29: Sales by Brand in $MM, 2008 – 2013
Figure 1.29: Sales Growth by Brand, 2008 – 2013
1.1.3.2.15 Other Drugs
Table 1.30: Sales by Type/Drug Name, 2008
Figure 1.30: Market Positions (Share) by Drug Name, 2008
Table 1.31: Sales by Brand in $MM, 2008 - 2013
Figure 1.31: Sales Growth by Brand, 2008 – 2013
1.2 Growth Trends for Global Generics and Biogenerics Drug Market, 2008 – 2013
Table 1.32: R&D for Global Biogeneric Drugs by Company/R&D Activities/Expected Market Entry
1.3 Summary of Global Generics and Biogenerics Drug Market, 2008 – 2013
1.3.1 Global Sales of Generic and Biogeneric Drugs, 2008 - 2013
Table 1.33: Global Sales of Generic and Biogeneric Drugs by Segment in $MM, 2008 - 2013
1.3.2 Global Prescription Volume for Generic and Biogeneric Drugs, 2008 - 2013
Table 1.34: Global Prescription Volume for Generic and Biogeneric Drugs by Segment in Millions, 2008 - 2013
1.3.3 Issues, Sales Drivers and Restraints
2. U.S. Market: Generic and Biogeneric Drugs
2.1 The Generic and Biogeneric Drug Landscape in the U.S.
2.1.1 U.S. Healthcare Spending and Patient Demographics
2.1.2 U.S. Prescription Volume for Generic and Biogeneric Drugs
2.1.3 U.S. Sales of Generic and Biogeneric Drugs
2.1.3.1 U.S. Sales of Generic and Biogeneric Drugs by Company
Table 2.1: U.S. Sales of Generic and Biogeneric Drugs by Company, 2008
Figure 2.1: U.S. Market Positions (Share) of Manufacturers of
Generic and Biogeneric Drugs by Company, 2008
2.1.3.2 U.S. Sales of Generic and Biogeneric Drugs by Category
Common Research Item
Table: Sales by Indication/Drug Name or Type/Drug Name, 2008
Figure: Market Positions (Shape) by Drug Name, 2008
Table: Sales by Brand in $MM, 2008 – 2013
Figure: Sales by Brand, 2008 – 2013
2.1.3.2.1 Allergy Drugs
2.1.3.2.2 Analgesics, NSAIDs and Antirheumatic Drugs
2.1.3.2.3 Anesthetics
2.1.3.2.4 Anti-Convulsants
2.1.3.2.5 Anti-Infectives
2.1.3.2.6 Cancer Drugs
2.1.3.2.7 Cardiovascular Drugs
2.1.3.2.8 CNS and Psychotherapeutic Drugs
2.1.3.2.9 Cholesterol Reducers/Statins
2.1.3.2.10 Diabetes Drugs
2.1.3.2.11 Gastrointestinal Drugs/Proton Pump Inhibitors
2.1.3.2.12 Hormonal Drugs
2.1.4.3.13 Osteoporosis and Hypercalcemia Drugs
2.1.4.3.14 Sleeping Agents
2.1.4.3.15 Other Drugs
2.2 Growth Trends for the U.S. Generics and Biogenerics Drug Market, 2008 - 2013
Table 2.31: R&D for U.S. Biogeneric Drugs by Company/R&D Activities/Expected U.S. Market Entry
2.3 Summary of U.S. Generics and Biogenerics Drug Market, 2008 - 2013
2.3.1 U.S. Sales of Generic and Biogeneric Drugs, 2008 - 2013
Table 2.32: U.S. Sales of Generic and Biogeneric Drugs by Segment in $MM, 2008 - 2013
2.3.2 U.S. Prescription Volume for Generic and Biogeneric Drugs, 2008 – 2013
Table 2.33: U.S. Prescription Volume for Generic and Biogeneric Drugs by Segment in Millions, 2008 - 2013
2.3.3 Issues, Sales Drivers and Restraints
3. European Market: Generic and Biogeneric Drugs
3.1 The Generic and Biogeneric Drug Landscape in the EU
3.1.1 EU Healthcare Spending and Patient Demographics
3.1.2 EU Prescription Volume for Generic and Biogeneric Drugs
3.1.3 EU Sales of Generic and Biogeneric Drugs
3.1.3.1 EU Sales of Generic and Biogeneric Drugs by Company
Table 3.1: EU Sales of Generic and Biogeneric Drugs by Company, 2008
Figure 3.1: EU Market Positions (Share) of Manufacturers of Generic and Biogeneric Drugs by Company, 2008
3.1.3.2 EU Sales of Generic and Biogeneric Drugs by Category
Common Research Item
Table: Sales by Indication/Drug Name or Type/Drug Name, 2008
Figure: Market Positions (Shape) by Drug Name, 2008
Table: Sales by Brand in $MM, 2008 – 2013
Figure: Sales by Brand, 2008 – 2013
3.1.3.2.1 Allergy Drugs
3.1.3.2.2 Analgesics, NSAIDs and Antirheumatic Drugs
3.1.3.2.3 Anesthetics
3.1.3.2.4 Anti-Convulsants
3.1.3.2.5 Anti-Infectives
3.1.3.2.6 Cancer Drugs
3.1.3.2.7 Cardiovascular Drugs
3.1.3.2.8 CNS and Psychotherapeutic Drugs
3.1.3.2.9 Cholesterol Reducers/Statins
3.1.3.2.10 Diabetes Drugs
3.1.3.2.11 Gastrointestinal Drugs/Proton Pump Inhibitors
3.1.3.2.12 Hormonal Drugs
3.1.3.2.13 Osteoporosis and Hypercalcemia Drugs
3.1.3.2.14 Sleeping Agents
3.1.3.2.15 Other Drugs
3.2 Growth Trends for the EU Generics and Biogenerics Drug Market, 2008 -2013
Table 3.32: R&D for EU Biogeneric Drugs by Company/R&D Activities/Expected Market Entry
3.3 Summary of EU Generics and Biogenerics Drug Market, 2008 - 2013
3.3.1 EU Sales of Generic and Biogeneric Drugs, 2008 - 2013
Table 3.33: EU Sales of Generic and Biogeneric Drugs by Segment in $MM, 2008 - 2013
3.3.2 EU Prescription Volume for Generic and Biogeneric Drugs, 2008 - 2013
Table 3.34: EU Prescription Volume for Generic and Biogeneric Drugs by Segment in Millions, 2008 - 2013
3.3.3 Issues, Sales Drivers and Restraints
4. Japanese Market: Generic and Biogeneric Drugs
4.1 The Generic and Biogeneric Drug Landscape in Japan
4.1.1 Japan Healthcare Spending and Patient Demographics
4.1.2 Japan Prescription Volume for Generic and Biogeneric Drugs
4.1.3 Japan Sales of Generic and Biogeneric Drugs
4.1.3.1 Japan Sales of Generic and Biogeneric Drugs by Company
Table 4.1: Japan Sales of Generic and Biogeneric Drugs by Company, 2008
Figure 4.1: Japan Market Positions (Share) of Manufacturers of Generic and Biogeneric Drugs by Company, 2008
4.1.3.2 Japan Sales of Generic and Biogeneric Drugs by Category
Common Research Item
Table: Sales by Indication/Drug Name or Type/Drug Name, 2008
Figure: Market Positions (Shape) by Drug Name, 2008
Table: Sales by Brand in $MM, 2008 – 2013
Figure: Sales by Brand, 2008 – 2013
4.1.3.2.1 Allergy Drugs
4.1.3.2.2 Analgesics, NSAIDs and Antirheumatic Drugs
4.1.3.2.3 Anti-Convulsants
4.1.3.2.4 Anti-Infectives
4.1.3.2.5 Cardiovascular Drugs
4.1.3.2.6 CNS and Psychotherapeutic Drugs
4.1.3.2.7 Cholesterol Reducers/Statins
4.1.3.2.8 Diabetes Drugs
4.1.3.2.9 Gastrointestinal Drugs/Proton Pump Inhibitors
4.1.3.2.10 Hormonal Drugs
4.1.3.2.11 Sleeping Agents
4.1.3.2.12 Other Drugs
4.2 Growth Trends for Japan Generics and Biogenerics Drug Market, 2008 - 2013
Table 4.25: R&D for Japanese Biogeneric Drugs by Company/R&D Activities/Expected Market Entry
4.3 Summary of Japan Generics and Biogenerics Drug Market, 2008 - 2013
4.3.1 Japan Sales of Generic and Biogeneric Drugs, 2008 - 2013
Table 4.26: Japan Sales of Generic and Biogeneric Drugs by Segment in $MM, 2008 - 2013
4.3.2 Japanese Prescription Volume for Generic and Biogeneric Drugs, 2008 - 2013
Table 4.27: Japan Prescription Volume for Generic and Biogeneric Drugs in Millions by Segment, 2008 - 2013
4.3.3 Issues, Sales Drivers and Restraints
5. Rest of World (ROW): Generic and Biogeneric Drugs
5.1 The Generic and Biogeneric Drug Landscape in the ROW
5.1.1 ROW Healthcare Spending and Patient Demographics
5.1.2 ROW Prescription Volume for Generic and Biogeneric Drugs
5.1.3 ROW Sales of Generic and Biogeneric Drugs
5.1.3.1 ROW Sales of Generic and Biogeneric Drugs by Company
Table 5.1: ROW Sales of Generic and Biogeneric Drugs by Company, 2008
Figure 5.1: ROW Market Positions of Manufacturers of Generic and Biogeneric Drugs by Company, 2008
5.1.3.2 ROW Sales of Generic and Biogeneric Drugs by Category
Common Research Item
Table: Sales by Indication/Drug Name or Type/Drug Name, 2008
Figure: Market Positions (Shape) by Drug Name, 2008
Table: Sales by Brand in $MM, 2008 – 2013
Figure: Sales by Brand, 2008 – 2013
5.1.3.2.1 Allergy Drugs
5.1.3.2.2 Analgesics, NSAIDs and Antirheumatic Drugs
5.1.3.2.3 Anesthetics
5.1.3.2.4 Anti-Convulsants
5.1.3.2.5 Anti-Infectives
5.1.3.2.6 Cancer Drugs
5.1.3.2.7 Cardiovascular Drugs
5.1.3.2.8 CNS and Psychotherapeutic Drugs
5.1.3.2.9 Cholesterol Reducers/Statins
5.1.3.2.10 Diabetes Drugs
5.1.3.2.11 Gastrointestinal Drugs/Proton Pump Inhibitors
5.1.3.2.12 Hormonal Drugs
5.1.3.2.13 Osteoporosis and Hypercalcemia Drugs
5.1.3.2.14 Sleeping Agents
5.1.3.2.15 Other Drugs
5.2 Growth Trends for the ROW Generics and Biogenerics Drug Market by Company/R&D Activities/Expected Market Entry, 2008 - 2013
Table 5.31: R&D for ROW Biogeneric Drugs
5.3 Summary of ROW Generics and Biogenerics Drug Market, 2008 - 2013
5.3.1 EU Sales of Generic and Biogeneric Drugs, 2008 - 2013
Table 5.32: ROW Sales of Generic and Biogeneric Drugs by Segment in $MM, 2008 - 2013
5.3.2 ROW Prescription Volume for Generic and Biogeneric Drugs, 2008 – 2013
Table 5.33: ROW Prescription Volume for Generic and Biogeneric Drugs by Segment in Millions, 2008 - 2013
5.3.3 Issues, Sales Drivers and Restraints
6. Activities of Generic and Biogeneric Drug Makers
Common Research Item
-Profile
-Contact
-URL
-Sales 2008
-Generic and Biogeneric Drug Sales 2008
-Generic Drug Categories
6.1 ~ 6.37 (Total 37 Companies)
7. Appendix
7.1 Selected Companies Mentioned in this Report
Table 7.1: Major Generic and Biogeneric Companies
To order this report:
Generic Drug Industry: Generic and Biogeneric Drugs for 15 Major Therapeutic Categories
CONTACT: |
|
Nicolas Bombourg |
|
Reportlinker |
|
Email: [email protected] |
|
US: (805)652-2626 |
|
Intl: +1 805-652-2626 |
|
SOURCE Reportlinker
Share this article